Application of intensive bronchial dilation test in airway reversibility evaluation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053803

Enrollment

Unknown

Registered

2021-11-29

Start date

2021-11-29

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary dysfunction

Interventions

Strong relaxation experimental group:1 mg salbutamol, 1 mg budesonide, 0.125 mg ipratropium inhaled within 1 hour for 3 cycles and then perform pulmonary function test

Control group:1 mg albuterol, 1 mg budesonide, and 0.125 mg ipratropium were inhaled once and then pulmonary function test was performed

Eligibility

Sex/Gender

All

Age

8 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with abnormal lung function.

Exclusion criteria

Exclusion criteria: Patients with chest tightness, dyspnea, or restrictive ventilatory dysfunction due to non-respiratory disease.

Design outcomes

Primary

Measure	Time frame
lung function;	—

Countries

China

Contacts

Public ContactSong Xicheng

Yantai Yuhuangding Hospital

drxchsong@163.com+86 535 6691999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026